OUR MISSION
Welcome to Swiss BioQuant, your premier bioanalytical contract research organization (CRO) specializing in LC-MS/MS and ligand-binding assays. Our mission is to advance scientific discovery and innovation through exceptional bioanalytical services. We are committed to delivering the highest quality results with precision and reliability, ensuring that our clients in the pharmaceutical and biotechnology sectors can trust us as their partner in research and development. Our dedication to scientific excellence, continuous improvement, and transparent communication drives us to exceed industry standards and contribute to the betterment of global health.
At Swiss BioQuant, we offer tailored LC-MS/MS and Ligand-Binding Assay method development, validation, and sample analysis in a 21 CFR part 11 compliant environment for both small and large molecules for your non-clinical and clinical studies. Our high standards of service enable us to meet the ever-increasing quality demands of leading pharmaceutical groups, both in content and documentation.
Our commitment to excellence is supported by continuous investments in employee training, documentation, and state-of-the-art instrumentation. Regular audits and inspections over the years have consistently validated our efforts and success in these areas.
THE EXPERTS IN BIOANALYSIS
Comprehensive Services for Small and Large Molecules
A premier bioanalytical Contract Research Organization (CRO) excels in providing a wide range of services dedicated to the analysis of both small and large molecules. Utilizing state-of-the-art High-Performance Liquid Chromatography coupled with Tandem Mass Spectrometry (HPLC-MS/MS), the CRO delivers precise and reliable quantitative analysis. This sophisticated technology ensures high sensitivity and specificity, making it ideal for the detection and quantification of analytes in complex biological matrices.
In addition to HPLC-MS/MS, the CRO also offers ligand-binding assays, which are pivotal for the analysis of large molecules such as proteins, peptides, and antibodies. These assays, known for their high throughput and robustness, are critical in pharmacokinetics (PK) and pharmacodynamics (PD) studies, providing essential data for the development of biopharmaceuticals.
The CRO's comprehensive bioanalytical services support the entire drug development process, from early-stage discovery to clinical trials, ensuring rigorous quality control and regulatory compliance. By combining advanced analytical methods with a deep understanding of molecular biology, the organization stands at the forefront of bioanalysis, driving innovation in therapeutic development.
With over 20 years of experience in LC-MS/MS and ELISA bioanalysis, we have successfully managed bioanalytical responsibilities for hundreds of studies, ranging from new drug entities to generics applications. Our expertise in drug, metabolite, and biomarker determination in preclinical and clinical studies is unparalleled.
We invite you to experience our expertise and dedication as an outsourcing partner for the pharmaceutical and biotech industry. We would be delighted to discuss your needs in a personal conversation. Please feel free to contact us directly.
Since 2008, Swiss BioQuant is regularly and successfully inspected by the Swiss authorities (Swissmedic), confirming the GLP compliance of our test facility according to the Swiss Ordinance relating to Good Laboratory Practice.
Bioanalysis for Cell and Gene Therapy
Expanding its expertise to the cutting-edge field of cell and gene therapy, the CRO employs quantitative Polymerase Chain Reaction (qPCR) technology. qPCR enables the precise quantification of nucleic acids, which is crucial for the bioanalysis of gene therapy products. This technique is invaluable for monitoring vector copy numbers, assessing gene expression levels, and ensuring the integrity and safety of gene-modified cells.
